News

ShortCut™️: The Only FDA-Cleared Leaflet Modification Solution for Streamlining Complex TAVR Procedures (interview)

TCTMD

Pi-Cardia Receives FDA Market Clearance for ShortCut™

BUSINESSWIRE

Pi-Cardia Receives FDA IDE Approval for Pivotal Study with ShortCut™ Device

ACCESSWIRE

First report of an IDE pivotal study of a dedicated splitting device during TAVR (interview)

PCR Online

ShortCut leads the way for leaflet modification (roundtable discussion)

PCR Online

Pivotal study on the ShortCut transcatheter aortic valve leaflet splitting device

EUROPCR DAILY NEWS

Leaflet modification before transcatheter aortic valve implantation in patients at risk for coronary obstruction: the ShortCut study

EUROPEAN HEART JOURNAL

Pi-Cardia Receives FDA Breakthrough Device Designation for ShortCut™

BUSINESSWIRE

Pi-Cardia Successfully Completes Enrollment in Pivotal Study for ShortCut™

BUSINESSWIRE

Pi-Cardia Hires Gary Gratson to Lead Global Commercialization

BUSINESSWIRE

First US Patient Successfully Treated with ShortCut™

ACCESSWIRE

First Dedicated Transcatheter Leaflet Splitting Device:
The ShortCut Device

EuroIntervention

Pi-Cardia Successfully Performs Mitral Valve Splitting With ShortCut™

ACCESSWIRE

News

Pi-Cardia ShortCut™ Device Successfully Treats First Patients in Europe

ACCESSWIRE

Pi-Cardia: Repair Rather than Replacement in TAVR

MedTech STRATEGIST

Leaflex: Changing the Conversation Around Aortic Stenosis?

Cardiovascular News

Pi-Cardia Successfully Treats First Patients with ShortCut™ Device

Businesswire

Press release - Venus Medtech to Partner With Pi-Cardia to Bring Its Leaflex™ Aortic Valve Technology to China

PRNewswire

Press release - Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners to Continue Clinical Trials with its Leaflex™ Aortic Valve Technology

Yahoo finance

Press release - Pi-Cardia Appoints Prof. Jacques Séguin
As Chairman

PRNewswire

TVT 2019:
Clinical Experiences with Pi-Cardia Leaflex Aortic Valve Remodeling: An Alternative to TAVR in Some Patients?

Dr. Martin B. Leon

PCR 2019:
Safety, Feasibility and Acute Performance of the Leaflex™
Performer when Used Pre TAVI in Aortic Stenosis Patients.
The Leaflex™ Performer Feasibility Study

Prof. Andreas Baumbach

Pi-Cardia’s Leaflex treatment improves aortic stenosis more than balloon valvuloplasty

BioWorld MedTech

Valve Leaflet Scoring Device for Aortic Stenosis Clears Feasibility Hurdle

tctMD/ the heart beat

Press release -Pi-Cardia First in Human Study Shows Significant Improvement in Aortic Valve Function Following Treatment with its Novel Non-Implant Based Leaflex™ Catheter

Yahoo finance

Press release -Pi-Cardia Successfully Completes
First in Human Studies with Novel Non-Implant Based
Treatment of Aortic Stenosis

Yahoo finance

TCT 2018: Innovation Gone Wild: The Pi-Cardia Leaflex™ Aortic Valve Remodeling System

Dr. Philippe Genereux

SHDS 2018: Pi-Cardia Leaflex™ Aortic Valve Remodeling: Experimental Findings and Early Human Experiences

Dr. Darren Mylotte

PCR 2017 Innovators Day: Pi-Cardia Leaflex™ performer

Prof. Andreas Baumbach

PCR 2016 Innovators Day: Pi-Cardia Leaflex™ Technology

Dr. Philippe Genereux

Press release - Pi-Cardia raises $10m

“Globes”- Israel business news

News

Press release - Venus Medtech to Partner With Pi-Cardia to Bring Its Leaflex™ Aortic Valve Technology to China

Press release - Pi-Cardia Appoints Prof. Jacques Séguin As Chairman

TVT 2019: Clinical Experiences with Pi-Cardia Leaflex Aortic Valve Remodeling: An Alternative to TAVR in Some Patients?

PCR 2019: Safety, Feasibility and Acute Performance of the Leaflex™ Performer when Used Pre TAVI in Aortic Stenosis Patients. The Leaflex™ Performer Feasibility Study

Pi-Cardia’s Leaflex treatment improves aortic stenosis more than balloon valvuloplasty

SHDS 2018: Pi-Cardia Leaflex™ Aortic Valve Remodeling: Experimental Findings and Early Human Experiences

PCR 2017 Innovators Day: Pi-Cardia Leaflex™ performer

PCR 2016 Innovators Day: Pi-Cardia Leaflex™ Technology

Press release - Pi-Cardia raises $10m

Press release - Pi-Cardia Appoints Prof. Jacques Séguin
As Chairman

TVT 2019:
Clinical Experiences with Pi-Cardia Leaflex Aortic Valve Remodeling: An Alternative to TAVR in Some Patients?

PCR 2019:
Safety, Feasibility and Acute Performance of the Leaflex™
Performer when Used Pre TAVI in Aortic Stenosis Patients.
The Leaflex™ Performer Feasibility Study